ALLOGENEIC RELATED DONOR STEM CELL TRANSPLANTATION IN AML CR1: ANY RISK FACTOR FOR BETTER SURVIVAL?

被引：0
|
作者：
Guvenc, S. [1 ]
Ozcelik, E. [2 ]
Hindilerden, F. [1 ]
Hasbal, N. [1 ]
Serefhanoglu, S. [2 ]
Kucukkaya, R. [1 ]
Arat, M. [1 ]
机构：
[1] Istanbul Bilim Univ, Hematol, Istanbul, Turkey
[2] Sisli Florence Nightingale Hosp, Hematol, Istanbul, Turkey
来源：
BONE MARROW TRANSPLANTATION | 2014年 / 49卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
PH-P036
引用
收藏
页码：S117 / S118
页数：2
相关论文
共 50 条
  • [21] ELN 2017 Risk Classification Predicts Survival of AML Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation
    Hansen, Doris K.
    Nieder, Michael L.
    Thompson, Zachary
    Kim, Jongphil
    Pidala, Joseph A.
    Nishihori, Taiga
    Khimani, Farhad
    Davila, Marco L.
    Mishra, Asmita
    Lazaryan, Aleksandr
    Sallman, David
    Elmariah, Hany
    Sweet, Kendra
    Liu, Hien
    Perez, Lia Elena
    Komrokji, Rami
    Fernandez, Hugo
    Lancet, Jeffrey E.
    Anasetti, Claudio
    Bejanyan, Nelli
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (03)
  • [22] GvHD and intensive chemotherapy prior to transplantation allow better leukaemic control in high risk CR1 AML after reduced-intensity conditioning HLA-identical allogeneic transplantation
    Faucher, C
    Boiron, JM
    Mohty, M
    Bay, J
    Perreau, V
    Bilger, K
    Vey, N
    Stoppa, AM
    Coso, D
    Ladaique, P
    Maraninchi, D
    Blaise, D
    BONE MARROW TRANSPLANTATION, 2004, 33 : S235 - S235
  • [23] Is an allogeneic stem cell transplantation a risk factor for poverty? Or professional consequences, which have an allogeneic stem cell transplantation?
    Seifart, U.
    Sohlbach, K.
    Vietzke, R.
    Peil-Grun, A.
    Neubauer, A.
    ONKOLOGIE, 2013, 36 : 163 - 163
  • [24] CR1 Favors PTCy-haplo over UCB in Allogeneic Stem Cell Transplantation for Adult Patients with AL
    Jo, Tomoyasu
    Ueda, Tomoaki
    Akahoshi, Yu
    Kondo, Tadakazu
    Uchida, Naoyuki
    Tanaka, Masatsugu
    Nakamae, Hirohisa
    Doki, Noriko
    Ota, Shuichi
    Sawa, Masashi
    Ohigashi, Hiroyuki
    Maruyama, Yumiko
    Takayama, Nobuyuki
    Nishida, Tetsuya
    Kanda, Yoshinobu
    Ichinohe, Tatsuo
    Atsuta, Yoshiko
    Arai, Yasuyuki
    BLOOD, 2023, 142
  • [25] Outcome of adult erythroleukemias in first complete remission (CR1) following autologous or allogeneic stem cell transplantation (SCT).
    Fouillard, L
    Labopin, M
    Gorin, NC
    Frassoni, F
    BLOOD, 2000, 96 (11) : 522A - 522A
  • [26] Whole Exome Sequencing of AML Cells Derived from Donor Cell Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation from Related Donor
    Kobayashi, Shinichi
    Kobayashi, Ayako
    Horiuchi, Toshikatsu
    Kato, Shoichiro
    Maekawa, Takaaki
    Yamamura, Takeshi
    Watanabe, Junichi
    Osawa, Yukiko
    Harada, Yuka
    Harada, Hironori
    Sato, Ken
    Kimura, Fumihiko
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2016, 22 (03) : S332 - S333
  • [27] Outcome of adult erythroleukemias in first Complete Remission (CR1) following autologous or allogeneic Stem Cell Transplantation (SCT)
    Fouillard, L
    Labopin, M
    Meloni, G
    Willemze, R
    Willemze, R
    Reiffers, J
    Prentice, H
    Schaefer, U
    Gorin, N
    Frassoni, F
    BONE MARROW TRANSPLANTATION, 2001, 27 : S82 - S82
  • [28] Reduced intensity conditioning (RIC) prior to allogeneic stem cell transplantation (SCT) for patients (PTS) with acute myeloid leukemia (AML) in first complete remission (CR1)
    Vey, N.
    Boiron, J. M.
    Faucher, C.
    Mohty, M.
    Bay, J. O.
    Bardoux, V. J.
    Perreau, V
    Coso, D.
    Pigneux, A.
    Blaise, D.
    ANNALS OF HEMATOLOGY, 2006, 85 : 27 - 27
  • [29] Allogeneic Stem Cell Transplantation: Risk Factor of HLA Incompatibility
    Brudermanns, Britta
    TRANSFUSIONSMEDIZIN, 2018, 8 (04)
  • [30] Allogeneic stem cell transplantation as a risk factor for recurrent melanoma
    Stevens, Hannah
    Raj, Kavita
    Ashby, Michael
    Grigg, Andrew
    LEUKEMIA & LYMPHOMA, 2018, 59 (07) : 1750 - 1752
12345